CRISM Therapeutics

CRISM Therapeutics is a clinical-stage pharmaceutical company specializing in the development of localized drug delivery systems for the treatment of solid tumors, with a primary focus on brain cancer. The company's proprietary Chemo-Resonant Intratumoural Slow-release Matrix (CRISM) technology utilizes a biodegradable polymer matrix to deliver high concentrations of chemotherapy directly into the tumor site while minimizing systemic toxicity. Its lead candidate, CT-001, is a reformulation of the chemotherapy agent temozolomide designed to be implanted during surgery for glioblastoma multiforme. By bypassing the blood-brain barrier and providing sustained drug release, CRISM Therapeutics aims to improve survival outcomes and quality of life for patients with aggressive cancers.